[Click eStock] "Hanall Biopharma, Clinical Trial Resumption Hopes... Stock Rebound Opportunity Arrives"

[Asia Economy Reporter Jang Hyowon] Hanyang Securities analyzed on the 13th that a rebound opportunity has come for Hanall Biopharma's stock price, which had been suppressed for six months.

Hanall Biopharma is the original developer of the autoimmune disease treatment ‘HL161’ with global competitiveness. The global rights of ‘HL161’ were licensed to Immunovant, and the Chinese rights were licensed to Harbor Biomed. In February, Immunovant voluntarily halted the US clinical trial of ‘HL161,’ causing the stock price to plummet by more than 40%.

On the same day, researcher Oh Byung-yong of Hanyang Securities stated in a report, “It has been over half a year since the US clinical trial was stopped,” and analyzed, “In cases like Hanall Biopharma, which voluntarily halted clinical trials, the trials usually resume within a few months, and the stock price recovers.”

Researcher Oh added, “Voluntary clinical trial suspension is one of the major buying opportunities for biotech companies,” and “Moreover, in the case of ‘HL161,’ there are clear grounds for resuming the trials, so the stock price is expected to rise as the clinical trial resumption approaches.”

He explained that positive momentum from the third quarter and the announcement of the Chinese clinical trial results are also forthcoming. He said, “On the 3rd, Immunovant’s parent company decided on an additional investment of 2 million dollars (approximately 23 billion KRW), which means the resumption of ‘HL161’ clinical trials,” and “Harbor Biomed, the Chinese partner, also announced on the 6th the clean success of the phase 2 Chinese clinical trial for ‘HL161’ in myasthenia gravis (MG).”

Furthermore, he predicted, “By the end of this year, the long-awaited MG US phase 3 clinical trial dosing is scheduled to begin, and the FDA IND submission related to the clinical trial resumption is expected to occur in the third to fourth quarter of this year, 2 to 3 months prior.” He also noted, “Harbor Biomed has completed phase 2 clinical trials for neuromyelitis optica and thrombocytopenia for ‘HL161,’ and will announce the results in the third quarter, which will also serve as a signal for the US clinical trial resumption.”